Drug Development, Protocols

Protocols: Calico recruits a machine learning star for computational biology; OncoMed raises $55M

Google is all about mastering computational biology these days. So it’s no wonder that its biotech startup, Calico, is putting a big effort together on machine learning.

Daphne Koller

Daphne Koller

Daphne Koller, formerly a professor at Stanford and co-founder of Coursera, has been recruited to head up Calico’s computational team, with plans to work directly with Google scientists on Calico’s R&D mission: improving human longevity. Said CEO Arthur Levinson: “Over the past three years, we have focused on building a world-class team of scientists who are studying the biological pathways of aging. With Daphne, we are bringing to Calico not only one of the world’s foremost experts in machine learning, but someone with a deep passion for understanding how these new technologies could bring forth insights into the biology of aging and disease.”

Redwood City, CA-based OncoMed Pharmaceuticals $OMED raised $55 million from the sale of shares. Most of that is earmarked for new R&D work.

A group of investors has acquired Novo Nordisk’s U.S. headquarters facility.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->